Q-omics provides the consensus-scored CDC20B profile across patient tissues and cancer cell-line models. CDC20B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, CDC20B is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, CDC20B RNA expression shows 13,483 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, KIRP, and TGCT as cancer lineages where CDC20B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC20B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC20B survival associations across molecular data types. CDC20B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC20B RNA expression–survival associations across cancer types. High CDC20B expression shows unfavorable associations in OV, LGG and MESO, but favorable associations in BRCA, UCEC and HNSC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for CDC20B RNA expression.
This table summarizes CDC20B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CDC20B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC20B shows lower tumor expression in KIRP, KIRC and LUSC and higher tumor expression in BRCA, LIHC and COAD. The KIRP box plot shows higher CDC20B RNA expression in normal versus tumor tissue (log2 FC = −0.801, t-test p < 0.001).
This table shows molecular features associated with CDC20B in patient tissues and cancer cell lines. In patient samples, CDC20B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC20B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
